Intravascular Lithotripsy Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Intravascular Lithotripsy Devices Market Trends and Insights

Rising Burden of Severely Calcified Coronary and Peripheral Artery Disease

The intravascular lithotripsy devices market is supported by an increase in complex calcium burden, rather than cardiovascular disease incidence alone. The cited global burden study reported 239 million prevalent ischemic heart disease cases and 122 million lower-extremity PAD cases in 2023. Aging, hypertension, diabetes, and chronic kidney disease increase the severity of vascular calcification in these patient populations. The 2025 clinical study found calcified lesions in 25%-50% of CAD patients undergoing PCI and linked inadequate modification with vascular complications and worse long-term outcomes^{[1]BMC Cardiovascular Disorders, “Efficacy and Safety of the SoniCracker Intravascular Lithotripsy Device for Severely Calcified Coronary Lesions: The LEAD-FIM Study From China,” BMC Cardiovascular Disorders, link.springer.com.}. Standard balloons are less suitable when calcium arc and thickness prevent adequate lesion preparation. Quality frameworks in the United States and Europe also place greater attention on stent expansion, which supports more complete calcium preparation before implantation.

Increasing Complexity of Percutaneous Coronary Intervention

The intravascular lithotripsy devices market benefits as physicians manage more multivessel disease, left-main disease, and calcified chronic total occlusions. These anatomical settings can result in inadequate stent expansion when conventional balloon angioplasty is used alone. A seven-center European registry of 454 patients found that IVL use in acute coronary syndrome cases increased over time, with p=0.004. A separate 2025 study reported intravascular imaging use in 94.3% of left-main IVL procedures, compared with 40.5% of non-left-main cases. These cases commonly combine IVL with IVUS, increasing the role of imaging and device planning within the procedure. The CT-IVL score achieved an AUC of 0.81 for predicting IVL need in the cited study, which can support more objective patient selection before entry to the catheterization laboratory.

Growing Clinical Evidence for Predictable Calcium Modification

The clinical evidence base has moved beyond early single-arm safety studies toward larger registries and broader patient groups. The 13,499-patient propensity-matched analysis associated IVL with lower 1-year mortality, myocardial infarction, and major adverse cardiovascular events than atherectomy. The same analysis reported 23% fewer 30-day procedural complications and 56% less procedural bleeding with IVL. IVL utilization surpassed atherectomy utilization after 2022, while evidence for below-the-knee, calcified nodule, and left-main use continued to develop. The VIGOUR trial reported 93.7% procedural success for MicroPort’s coronary IVL system in Chinese patients, extending the evidence beyond Western care settings. Late-2024 BENELUX-IVL registry results also showed comparable outcomes in patients aged 80 years and older, supporting use in a higher-risk geriatric group.

Improving Reimbursement for Coronary Intravascular Lithotripsy

Reimbursement is an immediate driver for the intravascular lithotripsy devices market in the United States. For calendar year 2026, CMS assigned CPT add-on code +92972 3.66 total relative value units and a national Medicare physician facility payment of USD 122^{[2]Centers for Medicare & Medicaid Services, “Coronary IVL 2026 Physician Reimbursement,” Shockwave Medical, shockwavemedical.com.}. Fiscal year 2025 inpatient MS-DRGs provided USD 10,000 in incremental payment over standard PCI with stent, effective October 1, 2024. This billing pathway offsets a portion of the single-use catheter cost for health systems operating under DRG constraints. Peripheral IVL reimbursement covers 8 HCPCS codes across iliac, femoral-popliteal, and tibial-peroneal territories under the 2025 OPPS Final Rule. The United Kingdom’s NICE guidance IPG780 created a formal assessment framework for IVL in peripheral arterial calcification in 2024. Such assessments can inform local coverage decisions across European payer systems.

High Single-Use Catheter Cost and Uneven Reimbursement Access

Single-use catheter pricing constrains the intravascular lithotripsy devices market, especially in systems without a dedicated payment route. Coronary IVL catheters carry list prices of USD 2,250-USD 4,750 per unit, while peripheral catheters reach USD 4,900 per unit. Multiple catheters can be required for complex lesions, which increases the cost of each procedure. Hospitals receiving global procedure payments may recognize the clinical benefit but lack a matching route to recover the device cost. This issue is more acute in emerging markets and can limit adoption to private networks with fee-for-service billing. Generator-free and simplified systems from Elixir Medical and FastWave Medical aim to reduce capital or per-procedure costs, although their reach remains investigational or limited in 2026.

Limited Comparative Evidence and Lesion-Access Constraints

Randomized long-term evidence against atherectomy remains limited, even though observational findings have been favorable for IVL. The 13,499-patient comparison may contain selection bias because physicians can direct less calcified or anatomically simpler cases toward IVL. Health technology assessment bodies seek randomized evidence and imaging-confirmed stent expansion results over 2-5 years before formal first-line endorsement. The FRACTURE IDE trial received FDA approval in December 2024, while Abbott’s 335-patient TECTONIC CAD IVL IDE trial began enrollment in April 2025. Their primary completion dates fall in 2026-2027, leaving a near-term evidence gap in formulary-led systems. Conventional balloon-based platforms also require a lesion that can be crossed, while forward-firing systems seek to address severe stenosis and chronic total occlusions where access is difficult.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Generator Platforms Are Emerging as a Contestable Layer

IVL Catheters and Balloons held 56.31% of the intravascular lithotripsy devices market share in 2025. This position in the intravascular lithotripsy devices market reflected the consumable role of catheter technology in each procedure and Shockwave Medical’s established catheter portfolio. Guidewires and Accessories remained the smallest product group. They benefit from below-the-knee treatment because distal tibial delivery requires hydrophilic-coated guidewires with strong pushability. Generators and Console Systems are projected to grow at a CAGR of 17.65% from 2026 to 2031. The intravascular lithotripsy devices market size for generator platforms is supported by new systems that require compatible consoles.

Generator growth continues despite the emergence of generator-free platforms such as Elixir LithiX HC-IVL. Boston Scientific Bolt, Abbott Coronary IVL, and Stryker AVS Pulse IVL each require facilities to consider compatible generator equipment. New regulatory clearances can therefore expand capital deployment before catheter procedure volumes increase. A 2025 study reported that IVUS-guided IVL independently achieved superior stent expansion compared with angiography-guided procedures. This relationship supports demand for imaging and accessory products alongside IVL. FastWave’s laser-based Sola system may change the cost structure if its feasibility findings are replicated at a commercial scale, but it remained an early-stage alternative in 2026.

By Vessel Type: Coronary Volume Coexists With Faster Peripheral Redefinition

Coronary vessels commanded 57.24% of revenue in 2025. This position in the intravascular lithotripsy devices market was built on Shockwave’s C2 and C2 Plus catheters and the Disrupt CAD clinical series across several coronary calcium presentations. The C2 Aero catheter received an instructions-for-use document in July 2025, adding a lower-profile iteration to the portfolio. Below-the-Knee Arteries are projected to expand at a CAGR of 18.22% from 2026 to 2031. The 30-day Disrupt PAD BTK II study reported 97.9% procedural success in 250 patients with mainly moderate-to-severe calcification.

One-year BTK II results presented in 2025 reported sustained safety and efficacy in a cohort that included 80% chronic limb-threatening ischemia and 70% diabetes. The results also reported low clinically driven target lesion revascularization rates and symptomatic improvement. These patient characteristics align with the growing prevalence of complex peripheral disease. Femoropopliteal and iliac procedures contribute meaningful revenue because 2025 reimbursement codes cover IVL across these vascular territories. The FORWARD PAD studies reported 99% technical success for the Javelin catheter. The forward-firing design reduces dependence on a pre-crossable stenosis, which broadens the procedures that can be considered for peripheral IVL.

By Technology: Balloon-Based Incumbency Faces Forward-Firing Competition

Balloon-Based IVL held 81.14% of revenue in 2025. Its position in the intravascular lithotripsy devices market reflects Shockwave Medical’s distribution scale and clinician familiarity with balloon-based treatment. Balloon delivery depends on the lesion anatomy that can be crossed before therapy. This limits use in some severe stenoses and total occlusions. Forward-Firing IVL is projected to grow at a CAGR of 18.42% from 2026 to 2031. The intravascular lithotripsy devices market size for this technology is supported by clinical demand in lesions where conventional balloon delivery is not feasible.

The Shockwave Javelin is a 5F non-balloon catheter with a 120-pulse forward emitter at its distal tip. It received FDA clearance in October 2024 and reported 99.0% technical success with a 1.1% major adverse event rate at 30 days in the cited studies. A 2026 clinical report described delivery while the catheter advances through severe stenosis or chronic total occlusions. IVUS-guided IVL also remains a distinct and growing treatment approach. The European registry recorded an increase in IVL used with intracoronary imaging, with p=0.002. Generator-free, laser-based, and hybrid systems were still sub-scale in 2026 but could increase technology choice as clinical studies and launches proceed.

By End User: Hospitals Lead While ASC Migration Changes Procedure Economics

Hospitals held 65.54% of revenue in 2025. Their role in the intravascular lithotripsy devices market reflected the concentration of catheterization laboratories, intravascular imaging, hemodynamic support, and specialized physician training in hospital settings. Cardiac catheterization laboratories represented the largest share of coronary IVL procedures within hospitals. Specialty vascular clinics increasingly perform peripheral IVL for patients with critical limb-threatening ischemia. These facilities can link treatment with wound-care pathways for the same patient population. Hospital demand remains central because complex coronary and peripheral cases require established procedural infrastructure.

Ambulatory Surgical Centers are projected to grow at a CAGR of 17.12% from 2026 to 2031. Cited consultants at TCT 2025 estimated that 25%-50% of cardiology procedures could move to ASCs. Government reimbursement preferences and hospital capacity planning support this shift. ASC cardiac accreditation standards influence whether facilities can safely introduce interventional cardiology procedures^{[3]Society for Cardiovascular Angiography and Interventions, “SCAI Position Statement on the Performance of PCI in Ambulatory Surgical Centers,” SCAI, scai.org.}. Illinois finalized an expansion in 2024 that allowed therapeutic and interventional cardiac catheterization in licensed ASTCs. State-level rules will continue to determine where outpatient IVL programs can be developed.

Geography Analysis

North America held 56.61% of the intravascular lithotripsy devices market share in 2025. The United States remains the main source of first-generation IVL clearances and the largest procedural volume country. Fiscal year 2025 MS-DRGs supplied USD 10,000 in incremental payment above standard PCI with a stent. Calendar year 2026 physician reimbursement includes USD 122 for the CPT add-on code +92972. These payments reduce the financial barrier for academic centers and regional hospital networks.

Canada and Mexico lag the United States in reimbursement maturity and device access, which limits the region’s share expansion. Europe remains the second-largest regional contributor to the intravascular lithotripsy devices market. Germany, the United Kingdom, France, Italy, and Spain account for most regional coronary and peripheral volume. The 454-patient European registry reported 98% device success and increasing IVL use with imaging and acute coronary syndrome treatment. Germany’s DRG structure accommodates reimbursement, while NICE IPG780 provides an evidence-review reference for peripheral calcification decisions in the United Kingdom.

Asia-Pacific is projected to grow at a CAGR of 18.65% from 2026 to 2031. Aging populations, calcified coronary disease, regulatory activity in China, and expanding cardiology capacity support the intravascular lithotripsy devices market size in the region. At least 5 domestically manufactured IVL systems had received NMPA approval in China by 2024, including MicroPort RotaPace’s TomaHawk system. Domestic competition can lower unit prices and extend access beyond leading hospitals. MicroPort’s intravascular piezoelectric guidewire system entered China’s Green Path review in June 2024, indicating work on guidewire-integrated designs. Japan and South Korea have established insurance coverage for coronary intervention, while Australian activity remains concentrated in metropolitan academic hospitals. The Middle East and Africa, and South America, remain smaller contributors, with adoption concentrated in private and academic centers and constrained by uneven reimbursement, currency volatility, and limited catheterization laboratory density.